← Back to Clinical Trials
Recruiting NCT05740735

NCT05740735 Emotional and Neutral Sounds for Neurophysiological Prognostic Assessment of Critically Ill Patients With a Disorder of Consciousness

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05740735
Status Recruiting
Phase
Sponsor Assistance Publique - Hôpitaux de Paris
Condition Disorder of Consciousness
Study Type OBSERVATIONAL
Enrollment 114 participants
Start Date 2024-03-25
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Use of "expressive" soundsHaving benefited from a prognostic evaluation by event related potentials (without sound research methods, only neutral sounds)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 114 participants in total. It began in 2024-03-25 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to determine if the use of emotional sound as subject own name (SON) pronounced by a familiar voice (FV) compared to SON pronounced by a non-familiar voice (NFV) during event related potential (ERP) produced a more reliable neurophysiological P300 responses, and to assess the prognostic value of this P300 responses induced by the SON with a FV.

Eligibility Criteria

Inclusion Criteria: * patients hospitalized in ICU for cardiac arrest, stroke, subarachnoid haemorrhage or head trauma, * persistent disorder of consciousness (DoC) 12 hours after sedation weaning or patient who has benefited from a prognostic assessment for persistent DoC and who has had in this assessment an evaluation by late PEA with MMN and P300 responses only to neutral sounds ("beep" and patient's first name pronounced by an unfamiliar voice) there is more than 6 months (since April 2022) Exclusion Criteria: * Moribund patient * Uncontrolled Shock during the neurophysiological evaluation * Sedated patient * Minor patient * brain death * Known deafness * Pregnant woman * Prior inclusion in the study * Patient not affiliated to a social security system * Implementation of limitations and stop of active therapies * Patient under legal protection * Patient benefiting from State Medical Aid

Contact & Investigator

Central Contact

Sarah Benghanem, MD, MSc, PhD student

✉ sarah.benghanem@aphp.fr

📞 0033158412533

Principal Investigator

Sarah Benghanem, MD, MSc, PhD student

PRINCIPAL INVESTIGATOR

Medical ICU Cochin Hospital, APHP.Centre

Frequently Asked Questions

Who can join the NCT05740735 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Disorder of Consciousness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05740735 currently recruiting?

Yes, NCT05740735 is actively recruiting participants. Contact the research team at sarah.benghanem@aphp.fr for enrollment information.

Where is the NCT05740735 trial being conducted?

This trial is being conducted at Paris, France, Paris, France.

Who is sponsoring the NCT05740735 clinical trial?

NCT05740735 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Sarah Benghanem, MD, MSc, PhD student at Medical ICU Cochin Hospital, APHP.Centre. The trial plans to enroll 114 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology